Finance Watch: Evotec, LianBio, IO Biotech Launch IPOs, Bringing US Total To 101

Two More Health Care SPACs Also Went Public

Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq. 

Finance Watch Public Company

Two of the largest biopharmaceutical initial public offerings in the US this year – both by companies headquartered outside of the US – were among the latest batch of IPOs. Evotec SE’s $435m offering was the year’s third-largest biopharma IPO and LianBio’s $325m offering closes out the 2021 top 10.

2021's Largest IPOs

  1. Sana Biotechnology Inc. $675.6m

The Evotec and LianBio offerings on 3 November and 31 October, respectively, also brought the US biopharma IPO total to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.